AstraZeneca is enjoying barnstorming growth in 2024 but is juggling big questions about its operations in China and ambitious plans to nearly double sales growth by 2030.
AstraZeneca Juggles Questions About China Scrutiny And US Growth Strategy
The UK-based major is set for near double-digit growth in 2024 but has become mired in concerns over a fraud probe in China on its third quarter call.
More from Earnings
More from Scrip
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.